Global Parkinson's Disease Drugs Market 2018-2023: Recent Drug Approvals are Driving Growth - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Global Parkinson's Disease Drugs Market - Segmented by Mechanism of Action and Geography - Growth, Trends, and Forecast (2018 - 2023)" report has been added to ResearchAndMarkets.com's offering.

The Parkinson's disease drugs market is expected to witness a CAGR of 6.2% during the forecast period, 2018-2023. The global Parkinson's disease drug market has witnessed a remarkable growth in the recent years, due to a large patient pool and increased diagnosis rates.

Recent Drug Approvals

Researchers are working to develop new and improved therapies for people with Parkinson's disease (PD). There have been many drugs that have been approved to treat Parkinson disease. In January 2015, the US FDA approved an extended release formulation of levodopa/carbidopa.

Recently in January 2018, Adamas Pharmaceuticals Inc. has launched Gocovri (amantadine extended-release capsules) for the treatment of dyskinesia in people with Parkinson's, who are taking levodopa. This is the first drug indicated specifically for dyskinesia, which is developed with the long-term usage of levodopa.

These newly-approved drugs, with different formulations, are addressing different unmet needs and are expected to drive the Parkinson disease drug market.

The other factors, which are also driving the market, include increasing demand due to the higher prevalence of the disease, new entrants expected to balance generic intrusion, and increasing use of the MAO-B inhibitor.

Key Highlights

• Generic Competition to Key Therapies - Restraining the Market
• Europe Holds the Largest Share of the Market

Major Market Developments

• Pfizer, the world's third-largest drug maker, announced that it is ending research to discover new medications for Alzheimer's and Parkinson's diseases, due to the high cost involved.
• Adamas Pharmaceuticals Inc. launched Gocovri (amantadine extended-release capsules) for the treatment of dyskinesia.

Companies Featured

• Merck & Co. Inc.
• Impax Laboratories Inc.
• Abbvie Inc.
• Mylan N.V.
• Boehringer Ingelheim
• GlaxoSmithKline plc
• Somerset Pharmaceuticals Inc.
• Teva Pharmaceuticals
• Pfizer
• Novartis AG
• Johnson & Johnson (Janssen)
• Allergan plc

Key Topics Covered

1. Introduction

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

7. Market Segmentation

8. Competitive Landscape

9. Key Players

10. The Future of the Market

For more information about this report visit https://www.researchandmarkets.com/research/629qdk/global?w=4